NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) posted its earnings results on Thursday, November, 7th. The company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.15. View Proteostasis Therapeutics' Earnings History.

Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Proteostasis Therapeutics.

3 equities research analysts have issued 12-month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Proteostasis Therapeutics' stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 406.8% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.

Media coverage about PTI stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Proteostasis Therapeutics.

Proteostasis Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,910,000 shares, a decrease of 5.4% from the January 15th total of 5,190,000 shares. Based on an average trading volume of 5,673,000 shares, the short-interest ratio is currently 0.9 days. Currently, 11.8% of the company's stock are sold short. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include Galera Therapeutics (GRTX), Stemline Therapeutics (STML), Minerva Neurosciences (NERV), Syros Pharmaceuticals (SYRS), Advanz Pharma (CXRXF), CytomX Therapeutics (CTMX), Evolus (EOLS), Concert Pharmaceuticals (CNCE), Spectrum Pharmaceuticals (SPPI), Albireo Pharma (ALBO), Lexicon Pharmaceuticals (LXRX), AMAG Pharmaceuticals (AMAG), MannKind (MNKD), Kamada (KMDA) and OptiNose (OPTN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Micron Technology (MU), Rite Aid (RAD), vTv Therapeutics (VTVT), Amarin (AMRN), Clearside Biomedical (CLSD), Syndax Pharmaceuticals (SNDX), Agile Therapeutics (AGRX) and Sorrento Therapeutics (SRNE).

(PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Proteostasis Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bain Capital Public Equity Management II LLC (1.45%), Oxford Asset Management LLP (0.97%), Acadian Asset Management LLC (0.52%), Connor Clark & Lunn Investment Management Ltd. (0.21%), 9258 Wealth Management LLC (0.04%) and National Asset Management Inc. (0.03%). Company insiders that own Proteostasis Therapeutics stock include Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View Institutional Ownership Trends for Proteostasis Therapeutics.

PTI stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Virtu Financial LLC. View Insider Buying and Selling for Proteostasis Therapeutics.

PTI stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Connor Clark & Lunn Investment Management Ltd., 9258 Wealth Management LLC and National Asset Management Inc.. View Insider Buying and Selling for Proteostasis Therapeutics.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.71.

Proteostasis Therapeutics has a market capitalization of $87.43 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics.

The official website for Proteostasis Therapeutics is http://www.proteostasis.com/.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]